Ceruloplasmin (2-D PAGE) Pattern and Copper Content in Serum and Brain of Alzheimer Disease Patients by Squitti, Rosanna et al.
205
Correspondence: Rosanna Squitti, AFaR Dept. of Neuroscience, Ospedale Fatebenefratelli, Isola Tiberina, 00186, 
Rome, Italy. Tel: +39 06 6837-385; +39 06 6837+300; Fax: +39 06 6837-360; Email: rosanna.squitti@afar.it
ORIGINAL RESEARCH
Ceruloplasmin (2-D PAGE) Pattern and Copper Content in 
Serum and Brain of Alzheimer Disease Patients
Rosanna Squitti
1, Carlo C. Quattrocchi
2, Gloria Dal Forno
3, Piero Antuono
4, 
David R. Wekstein
5, Concetta R. Capo
6, Carlo Salustri
7 and Paolo M. Rossini
1,3,8
1AFaR, Dept. of Neuroscience, Fatebenefratelli Hospital, Rome, Italy. 
2Depts. of Radiology “Campus 
Biomedico” University, Rome, Italy. 
3Depts. of Neurology, “Campus Biomedico” University, Rome, Italy. 
4Dept. of Neurology, Medical College of Wisconsin, Milwaukee, WI, U.S.A. 
5University of Kentucky 
Alzheimer’s Disease Research Center, Lexington, KY, U.S.A. 
6Dept. of Biology, Tor Vergata Uni-
versity, Rome, Italy. 
7Institute of Cognition Sciences and Technologies (CNR), Rome, Italy. 
8IRCCS 
‘Centro S. Giovanni di Dio-FBF’, Brescia, Italy.
Abstract: A dysfunction in copper homeostasis seems to occur in Alzheimer’s disease (AD). We previously evidenced that 
an excess of non-ceruloplasmin-copper (NCC) correlated with the main functional, anatomical as well as cerebrospinal 
markers of the disease. Aim of our study was to investigate ceruloplasmin isoforms as potential actors in this AD copper 
dysfunction. Our data show that AD patients have ceruloplasmin fragments of low molecular weight (<50 kDa) both in their 
serum and brain, contrary to healthy controls. Ceruloplasmin isoforms of higher molecular weight (115 and 135 kDa in 
serum and 135 kDa in brain), as well as copper levels in the brain, instead, do not seem to mark a difference between AD 
and healthy subjects. These data suggest a ceruloplasmin fragmentation in the serum of AD patients. Some clues in this 
direction have been found also in the AD brain.
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Introduction
Alzheimer’s Disease (AD) is a heterogeneous, progressive neurodegenerative disorder representing the 
most common cause of dementia in the elderly. There is compelling evidence that in this disease beta 
amyloid (Aβ) deposition triggers oxidative stress as well as anomalous metal—Aβ protein interaction. 
Recent studies have shown that metals such as copper, iron and zinc are key mediating factors in these 
processes. High concentrations of copper and iron are found within senile plaques and neuroﬁ  brillary 
tangles of AD brains (Smith et al. 1997; Lovell et al. 1998; Sayre et al. 2000). Both metals can catalyze 
Fenton’s reactions, generating a ﬂ  ux of reactive oxygen species that can potentially damage functional 
and structural macromolecules (Smith et al. 1997). Moreover, the amyloid precursor protein (APP) is 
a crucial regulator of neuronal copper homeostasis (Barnham et al. 2003) and an abnormal brain homeo-
stasis of metals could contribute to set up chemical conditions where toxicity and deposition of Aβ are 
promoted (Bush, 2002). These phenomena could be due simply to aging or to variations in levels of 
circulating blood copper (Bush, 2002). In fact, recent evidence showed that in a model of cholesterol 
fed rabbits, the ingestion of ≈2 µM of copper in drinking water markedly changed the brain β-amyloid 
burden with no variation of serum ceruloplasmin levels. This suggests that ingested copper supplied 
the serum exchangeable copper pool (Sparks and Schreurs, 2003).
The debate on the toxic or protective role of copper in AD is still ongoing. In opposition to some 
studies supporting copper toxic role (White et al. 1999; Huang et al. 1999) and a copper elevation in 
AD (Squitti et al. 2002; Ritchie et al. 2003; Smorgon et al. 2004; Squitti et al. 2004; Bomboi et al. 2005; 
Squitti et al. 2006), new studies support the notion of a protective role of this metal (Bayer et al. 2003; 
Phinney et al. 2003; Pajonk et al. 2005; Kessler et al. 2006). Moreover, differences in ceruloplasmin 
and cholesterol levels were observed between AD patients and controls supporting a role of cholesterol 
in AD and a possible inﬂ  uence of increasing circulating copper levels (Sparks et al. 2005). Actually, 
copper distribution in AD is very complex. Indeed, new evidence suggests that copper in brain may 
redistribute outside the cell, leaving the cell relatively deﬁ  cient (Religa et al. 2006).
Copper is a cofactor of several intracellular enzymes, including cytochrome oxidase, copper-zinc 
superoxide dismutase and lysyl oxidase (Gubler et al. 1952). Over 90% of copper contained in human 
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serum is considered bound to ceruloplasmin, 
making this protein a central constituent of copper 
transport and metabolism. Although past studies 
in man have found no differences in serum copper 
levels between AD and controls (Molina et al. 
1998; Ozcankaya and Delibas, 2002), more recent 
studies have shown both an increase (Gonzàlez 
et al. 1999; Squitti et al. 2002; Ritchie et al. 2003; 
Smorgon et al. 2004; Bomboi et al. 2005, Squitti 
et al. 2006) and a decrease of these levels (Pajonk 
et al. 2005; Kessler et al. 2006). This seemingly 
bi-directional behavior is probably due to the fact 
that absolute levels of serum copper are considered: 
when only the non-ceruloplasmin-copper (NCC) 
fraction is considered, discrepancies are actually 
attenuated. For example, a value of 4 µM of NCC 
can be calculated from data reporting low levels 
of total serum copper in AD (Kessler et al. 2006). 
This is substantially higher than 1.6 µM, which 
represents the upper value of the NCC normal 
reference range in healthy populations (Hoogen-
raad, 2001). This suggests that it is the cerulo-
plasmin-copper relationship that represents the key 
to interpret copper ﬁ  ndings in AD living patients, 
rather than absolute serum copper levels. It is upon 
this assumption that we focused our study on the 
alterations in the protein structure and on the 
composition of the whole ceruloplasmin protein 
as isoforms, expressing pattern changes or protein 
post-transductional modiﬁ  cations (Brenner, 2003; 
Squitti et al. 2005 and 2006).
We had already demonstrated that the loosely 
bound copper fraction (NCC) is speciﬁ  cally higher 
than normal in AD patients (Squitti et al. 2005), that 
it has blood brain barrier ﬁ  ltering properties, and that 
it correlates with markers of neurodegeneration of 
AD in the CSF, namely β-amyloid, h-tau and p-tau 
(Squitti et al. 2006). We report here on the qualitative 
changes of ceruloplasmin in the serum of AD patients 
explored by means of a two dimensional polyacryl-
amide gel electrophoresis (2-D PAGE) approach. We 
also report on a preliminary investigation on cerulo-
plasmin in AD brain tissues.
Materials and Methods
The study was approved by the local IRB and all 
participants or legal guardians signed an informed 
consent. Brain tissues from AD patients were 
kindly provided by the Brain Bank of the Medical 
College of Wisconsin, USA and those from control 
cases by the Biologically Resilient Adults in 
Neurological Studies (BRAINS) project (Schmitt 
et al. 2001).
Tissues
Serum and brain samples were obtained from 
different AD patients, as they could not be obtained 
from the same subject. Serum—samples of fresh 
serum were obtained from 25 individuals with a 
diagnosis of probable AD, (NINCDS-ADRDA 
criteria) (McKhann et al. 1984) and a Mini-Mental 
State Examination (MMSE) (Folstein et al. 1975) 
score of 25 or less (ages 65–81 years, mean = 75 
years), and 25 age- and sex-matched cognitively 
normal individuals (ages 64–89 years, mean = 76.1 
years), MMSE (mean = 28). Criterion for exclusion 
of both patients and controls was presence of 
conditions affecting copper metabolism and 
biological variables of oxidative stress (e.g. 
diabetes mellitus, inﬂ  ammatory diseases, Hodg-
kin’s disease, recent history of heart or respiratory 
failure, chronic liver or renal failure, malignant 
tumors, alcohol abuse). Serum samples from AD 
patients and controls were pooled. Ceruloplasmin 
content in both pools was made to 28 mg/dL and 
each serum sample contributed equally to cerulo-
plasmin content. Serum pools were precipitated in 
an 8:1 v/v 100% methanol. The samples were kept 
at –20° C for 2 h and then centrifuged at 13000 
rpm for 30 min at 4°C. The supernatant was 
discarded and the pellet resuspended in 450 µl of 
a solution for isoelectric focusing (IEF) (2D PAGE 
sample buffer), containing 8 M urea, 2% CHAPS, 
0.3% DTT, 0.5% Ampholine pH 3.5–10 and traces 
of bromophenol blue.
Tissues from the cerebral cortex, including 
temporal neocortex, were obtained from 9 cases 
of AD NINCDS-ADRDA (McKhann et al. 1984) 
(ages 80–91 years, mean = 84.6; postmortem 
interval (PMI) 1–7.5 h, mean = 4.3 h), conﬁ  rmed 
histopathologically at autopsy (Khachaturian, 
1985), along with 10 control cases (ages 73–87 
years, mean = 80.2 years; PMI 1–6 h, mean 3.6 h). 
Neuritic plaques were counted on silver stained 
serial sections according to previously reported 
methods (Yamamoto and Hirano, 1986). 
Preparation of brain samples for SDS PAGE 
or 2D-PAGE analyses
Brain samples from the associative cortex (area 9), 
were weighted, homogenized in a 3x w/v (10mM 
HEPES, 10mM NaCl, 1mM KH2PO4, 5mM 
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NaHCO3, 1mM CaCl2, 0.5mM MgCl2; 4°C) 
containing a protease inhibitor mixture (2 mg/mL 
leupeptin, 1 µg/mL pepstatin, 0.1 mg/mL PMSF) 
and sonicated with 10 strokes at 4°C (IKA 
LABORTECHNIK). Protein concentration was 
determined using a Dc Protein Assay kit (Bio-Rad 
Laboratories, Hercules, CA, U.S.A.) based on 
Lowry et al. (1951). Brain homogenate aliquots with 
equal protein content from AD and control sample 
were pooled separately. Homogenates were, subse-
quently, fractionated using a previously reported 
method (Guillemin et al. 2005): brieﬂ  y, 0.1 volumes 
of a 2.5M sucrose solution was added to the pool, 
centrifuged at 11000 rpm for 10 min at 4°C, the 
pellet stored at –80°C and the supernatant centri-
fuged again at 14000 rpm (3 h at 4°C). The second 
supernatant was desalted, then dehydrated using a 
refrigerated SpeedVac Plus centrifuge (ThermoSa-
vant Instruments Inc., Holbrook, NY, U.S.A.), and 
ﬁ  nally resuspended in either SDS PAGE or 2D-
PAGE sample buffer and stored at –80°C.
Copper and ceruloplasmin content 
measurements
Serum copper concentration was measured by both 
methods of Abe et al. (1989) (Randox Laboratories, 
Crumlin, U.K.), and an A   Analyst 300 Perkin 
Elmer atomic absorption spectrophotometer 
equipped with a graphite furnace with platform 
HGA 800. Serum ceruloplasmin was measured by 
immunoturbidimetric assay using a rabbit anti-
human ceruloplasmin antibody in phosphate buffer 
(Roche, Diagnostic, Germany). Copper estimation 
by the Abe’s method and ceruloplasmin measures 
were automated on a Hitachi 917 analyser (Roche 
Diagnostics) and performed in triplicate. For each 
serum copper and ceruloplasmin pair contributing 
to the AD and control pool, the copper bound to 
ceruloplasmin (CB) and the loosely bound fraction, 
referred to as non-ceruloplasmin-bound copper 
(NCC), were calculated. Copper bound to cerulo-
plasmin was computed as follows (Walshe, 2003): 
CB = n * ceruloplasmin mg/L; n = 0.0472 (µmol/
mg). By subtracting CB from the total serum 
copper, the “non ceruloplasmin bound copper” 
(NCC) value was estimated (Stremmel et al. 1991; 
Walshe, 2003; Twomey et al. 2005).
For brain copper quantitation, frozen brain 
specimens were weighted and homogenized in a 
3x w/v. A hundred µl of brain extracts were diluted 
to 150 µl of dH2O and an equal volume (150 µl) 
of a 65% nitric acid solution was added. After 1 
week of digestion, atomic absorption was measured 
by an atomic absorption spectrophotometer.
Electrophoresis and Immunoblotting
SDS-PAGE were performed on 10% SDS-poly-
acrylamide separating gels, run at constant 15 mA 
(15’) through the stacking gel, and at constant 30 
mA through the separating gel. Proteins were 
transferred to nitrocellulose membranes (Bio-Rad 
Laboratories, CA, U.S.A.) at 4°C (60 V, 2h), 
blocked in TBS containing 0.2% Tween-20 and 
10% non-fat dry milk (1h at room temperature) 
and incubated with a 1:10,000 goat anti-human 
ceruloplasmin antibody solution (1h at RT) (Sigma-
Aldrich Corporation, St. Louis, MI, U.S.A.). Films 
were developed by incubating membranes with 
1:80,000 HRP-conjugated anti-goat secondary 
antibody solution and using an enhanced luminol 
reagent (Perkin Elmer Life Sciences, Boston, 
U.S.A.). Kodak ﬁ  lms were used.
2-D PAGE were performed on a Protean IEF 
Cell (Bio-Rad Laboratories, CA, U.S.A.) for about 
25 KVh after the dry 17 cm pH 4.5–5.7 and the 
7cm pH 3–10 IPG strips (Bio-Rad Laboratories, 
CA, U.S.A.) were rehydrated with the sample solu-
tion; the strips were then equilibrated and run on 
a second dimension 10% or 7–20% gradient poly-
acrylamide gel. Proteins were transferred to nitro-
cellulose membranes and developed with a speciﬁ  c 
polyclonal anti-human ceruloplasmin as described 
above. Four gel replicates of each pooled sample 
per experiment were performed and developed on 
the same ﬁ  lm to avoid procedural bias in the optical 
density reading (intra-run variation assay). Then, 
three sets of experiments were performed to assess 
the inter-run variation. Analysis of 2D PAGE ﬁ  lms 
was performed by using PDQuest 2-D analysis 
software (Bio-Rad Laboratories, CA, U.S.A.), 
creating a master map from match data sets of 4 
replicates and comparing optical density of AD 
pool vs. control pool. The same procedure analysis 
was followed on serum and brain samples.
Results
Copper concentration in the serum of 
patients with AD is higher than controls
In Table 1, levels of serum copper biological vari-
ables expressed as mean (SD) of individual 
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concentrations contributing to patient or control 
pools, are reported. Serum copper in the AD group 
was higher (p < 0.001) while differences in ceru-
loplasmin and copper bound to ceruloplasmin 
concentrations between AD and control samples 
were not evident (p = 0.369). The amount of the 
calculated NCC was higher in AD (test t, p = 0.001) 
when compared to controls.
Ceruloplasmin 2D map in serum of AD 
patients and controls
To reveal qualitative isoform differences in serum 
ceruloplasmin between AD and controls, 2-D 
PAGE experiments were carried out by pooling 
sera weighted for the same amount of cerulo-
plasmin (28 mg/dL) per sample. No gross changes 
were revealed for the 135 and 115 kDa molecular 
weight forms (Figure 1). The immunoblotting 2-D 
maps showed various spots in the pH 4.5–pH 5.7 
range, resolving the 135 and the 115 kDa band 
(Figure 1), usually detected on ceruloplasmin SDS-
PAGE. The main difference between AD and 
control ceruloplasmin was the presence of lower 
molecular weight spots (<50 kDa) in the AD, not 
detected in control serum. Analysis of the separated 
135 kDa and 115 kDa spots, identiﬁ  ed on a master 
map created by using the PDQuest analysis soft-
ware, showed no qualitative differences for spots 
composing of the 135 and 115 kDa forms, 
suggesting that the spectrum of ceruloplasmin 
isoforms was substantially superimposable 
between AD and control samples (Figure 2). By 
2-D PAGE analysis, it was possible to identify 8 
spots at 135 kDa and 5 ones at 115 kDa. Quantita-
tive analysis of optical density of the separated 
spots showed a relative >50% different density in 
ﬁ  ve identiﬁ  ed spots labelled 1 to 5 in Figure 2. The 
ceruloplasmin spots 1, 2 and 5 were decreased, 
while spots 3 and 4 were increased in AD of at least 
50%. However, the variability experienced during 
different trials allowed us to rule out a signiﬁ  cant 
relevance of these differences.
Ceruloplasmin is detected in brain samples 
from AD and control subjects
The SDS PAGE study of brain extracts was devel-
oped in 2 steps. In a preliminary one, AD and 
control samples were run following standard SDS 
PAGE protocols. Using this procedure both 
samples showed a band at a high molecular weight, 
named 200 kDa band (Figure 3A). Subsequently, 
strong reducing conditions were used (2 µl of beta-
mercaptoethanol incubation 5 minutes before 
loading), resulting in the disappearance of the 200 
kDa, and the resolution of the 135 kDa band 
(Figure 3B). In the control sample the 135 kDa was 
the only band resolved, while in the AD sample, 
few lower molecular weight bands were evident 
(Figure 3B). Low molecular weight bands in the 
AD brain sample might be referred to AD proteo-
lytic processes occurring in the living patient or to 
processes of post-mortem or sample storage degra-
dation. To assess if low molecular weight bands in 
the AD brain specimen could be referable to 
processes of degradation speciﬁ  c of AD, the control 
sample was incubated 3 h at 30°C with 1/10 v/v of 
the AD sample. In this case, low molecular weight 
fragments of ceruloplasmin in the control pool 
were not generated. Instead, a high molecular 
weight smear was visualized even at strong 
reducing conditions, possibly accounted for the 
formation of high molecular weight agglomerates 
in the presence of AD ceruloplasmin fragments. 
The control sample alone in the same conditions 
did not show either degradation products or high 
molecular weight agglomerates (Figure 3C).
Pellet samples also showed a relative amount 
of membrane-bound ceruloplasmin (Fig. 3B).
Two-dimension PAGE experiments carried out 
on AD brain samples detected 4 spots at 135 kDa, 
Table 1. Serum copper and ceruloplasmin in controls and AD patients.
  AD patients(n = 25)  Controls(n = 25)  test t
Serum Copper (µmol/L)  18 (6)  13.2 (2.2)  p < 0.001
Ceruloplasmin (mg/dL)  27.9 (6.2)  26.5 (4.3)  p = 0.369
Copper bound to
ceruloplasmin (µmol/L)  13.1 (2.9)  12.5 (0.4)  p = 0.369
Non-ceruloplsmin-copper (NCC)
(µmol/L)  4.9 (5.6)  0.7 (1.9)  p = 0.001
Data are presented as means (SD). Signiﬁ  cant at the p = 0.05 level.
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and some smaller fragments in the 40–50 kDa 
range, reproducing the evidence of the 2D PAGE 
of serum ceruloplasmin (Musci et al. 1993). In the 
brain specimens of both AD and controls the 115 
kDa isoforms, characteristic of the ceruloplasmin 
in serum, were not detected. The same experiments 
performed on control brains did not successfully 
show interpretable spots (Fig. 3D).
The average of the neuritic plaques load 
counted in AD specimens was 33 (5.6). Copper 
was also separately quantiﬁ  ed in each cortical 
tissue sample, and did not differ between the two 
groups (Table 2). 
Discussion 
The main result of our study was the identiﬁ  cation 
of fragments of ceruloplasmin proteolysis both in 
the serum and in the brains of AD patients. The 
evidence of ceruloplasmin fragmentation suggests 
that at least a portion of ceruloplasmin is present 
as protein apoform and that impairment in the 
incorporation of copper into the protein may occur 
during its biosynthesis. This seems to be the main 
change in the ceruloplasmin structure: our data 
demonstrate that the ceruloplasmin isoform proﬁ  le 
is not qualitatively different in AD patients than in 
healthy controls in terms of molecular weight and 
Figure 1. 2D analysis of serum ceruloplasmin in AD (A) and control (B). The pH 5–5.7 range is shown. Note how similar is the protein pat-
tern at about 135 and 115 kDa. Low molecular weight (<50 kDa) positive spots are present only in AD serum (B). 450 µl of a 1.5 mg/mL 
protein solution were loaded per gel. Ceruloplasmin content in both pools was made to 28 mg/dL and each serum sample contributed 
equally to the ceruloplasmin content.
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protein isoelectric pH. However, alternative 
hypotheses could be put forward to explain ceru-
loplasmin fragmentation. In particular, it could be 
caused by oxidative insult as a result of incorrect 
or overloading of copper into the protein, or an up 
regulation of redox active enzymes causing a 
general increase in oxidative stress or a down 
regulation in enzymes that normally regulate 
oxidative stress; both forms of enzyme would be 
susceptible to changes in copper homeostasis as 
has been reported to occur in Alzheimer’s disease. 
Further studies are needed to explore these alterna-
tive hypothesis even though the limited amount of 
AD patients samples is an important limiting 
factor.
Ceruloplasmin apoprotein is excessively 
secreted by hepatocytes in the presence of copper 
incorporation impairment, because of a dysfunction 
of the copper–transporting ATPase 7b, as it occurs 
in Wilson’s disease (Bielli and Calabrese, 2002). 
The idea of an impairment of copper incorporation 
into the ceruloplasmin protein in AD comes from 
the notion that the ceruloplasmin apoprotein is 
rapidly degraded in plasma (Bielli and Calabrese, 
Figure 2. 2D quantitative analysis of serum ceruloplasmin isoforms at 135 and 115 kDa. A master map created by using PDQuest software 
from a triplicate of AD sample and a quadruplicate of control sample. The optical density analysis of the spots did not show statistically 
signiﬁ  cant differences between AD and control sample.
Table 2. Brain copper measurements in controls and AD patients.
  AD patients(n = 9)  Controls(n = 10)  test t
Total Protein (mg/mL)  0.79 (0.34)  1 (0.24)  p = 0.036
Copper/Protein (ng/mg wet weight)  5.126 (1.59)  6.77 (1.52)  p > 0.1
Data are presented as means (SD). Signiﬁ  cant at the p = 0.05 level.
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2002). The presence of ceruloplasmin fragments 
<50 kDa in AD suggests a similarly impaired 
copper transfer into the secretory pathway of hepa-
tocytes. Ceruloplasmin degradation could, then, 
partially account for the rise of the NCC compo-
nent. Even if the NCC mean value in AD reaches 
a level 9 times lower than that found in Wilson’s 
disease, it is still sensibly higher than the value 
found both in our controls and in the general healthy 
population (0–1.6 µmol/L) as also arguable from 
data presented by other authors (Kessler et al. 
2006). Moreover, we recently obtained preliminary 
data of a ﬁ  ltered unbound copper component in AD 
3.7 times higher than the value in healthy controls 
(Squitti et al. 2006). Both ultraﬁ  ltration and the 
2D-PAGE data support an impairment of copper 
incorporation into ceruloplasmin and a possible 
defect in biliary copper excretion, as some authors 
have suggested (Bush, 2004).
The proﬁ  le of ceruloplasmin isoforms at 115 
and 135 kDa in serum reported in the present study 
is consistent with previous evidence in normal 
aging (Musci et al. 1993), and the isoforms of the 
135 and 115 KDa bands were qualitatively similar 
in AD and controls.
The low MW bands observed in the brain 
suggest that ceruloplasmin fragmentation may 
occur also in the brain of AD patients. In our 
experiment, where a brain control sample was 
incubated for 3 h at 30°C together with 1/10 v/v 
of the AD sample, no ceruloplasmin proteolysis 
took place, suggesting that the fragmentation is not 
Figure 3. Brain ceruloplasmin shows proteolysis products in AD sample. A. Monodimensional SDS-PAGE performed in the absence of β-
mercapto-ethanol shows a higher amount of the 115 kDa isoform in the AD sample. A ≅ 200kDa band is indicated by the arrow; B. Same as 
Panel A in the presence of β-mercapto-ethanol shows disappearance of the ≅ 200 kDa band, lower molecular weight fragments in the AD 
sample and presence of ceruloplasmin in cytosol and membrane fractions; C. Control sample shows a sharp band at the expected MW, 
even after 3 hours incubation at 30°C, whereas a smear at higher molecular weight appears when it is incubated in presence of 1/10 of the 
AD sample; D. 2D map of a brain extract from AD patients shows few spots at the full-length MW and some intense spots at lower molecu-
lar weight (<50 kDa). Cpl, ceruloplasmin; ctrl, control; AD, Alzheimer disease; plt, membrane fraction; sup, cytosol fraction.
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due to processes of post-mortem or sample storage 
degradation, but rather to AD-related degeneration 
processes, which took place during the patient’s 
life. Moreover, our experiment allowed to mark 
the moment in the ceruloplasmin lifetime when the 
fragmentation took place. In fact, the control 
sample did not show any fragmentation after the 
incubation, indicating that the AD-related degrada-
tion did not act upon a properly formed cerulo-
plasmin molecule but rather upon its apoform, i.e. 
during its biosynthesis. 
The 115 kDa band was not detectable in the 
brain tissue, either with SDS PAGE or 2D-PAGE. 
Our ﬁ  ndings are in line with results previously 
reported for the Glycosylphosphatidylinositol-
anchored (GPI) form of ceruloplasmin, synthesized 
in mammalian astrocytes (Patel and David, 1997). 
Indeed these authors revealed an electrophoretic 
band at the MW of 135 kDa for the GPI form. 
When we carried out the SDS PAGE resolution 
of ceruloplasmin from brain samples with standard 
procedures, we evidenced a band at 200 kDa MW, 
both in AD and in control specimens, which has 
been reported by at least one author (Sato et al. 
1990). However, when these two fractions were 
further analysed by denaturing SDS-PAGE, the 
200 kDa band was no more detectable, as also 
described by Sato and colleagues (1990), and only 
the 135 kDa band could be resolved in both 
samples (Figure 3B). These ﬁ  ndings suggest that 
the band at high MW may be the result of cerulo-
plasmin chain aggregation of the apparent weight 
of 200 kDa.
2-D PAGE resolved the 135 kDa MW band in 
brain samples in 4 distinct isoforms of cerulo-
plasmin. Our data extend previous evidence of a 
single polypeptide species, identiﬁ  ed as the GPI 
anchored form of ceruloplasmin (Patel and David 
1997). In fact, we used a polyclonal antibody with 
a broad spectrum of antigen afﬁ  nity, which might 
account for the larger number of isoforms we 
found.
The difﬁ  culties we experienced in detecting 
ceruloplasmin in 2D experiments with controls—
in which we started from brain crude extracts—
under the same conditions as in AD, suggest that 
the amount of ceruloplasmin in AD was higher 
than in control brains, in agreement with previous 
literature (Loefﬂ  er et al. 1996; Deibel et al. 1996; 
Castellani et al. 1999).
We found that AD brain specimen had copper 
content similar to controls, reproducing previous 
(Platin et al. 1997) an recent results (Religa et al. 
2006), even though other authors (Deidel et al. 
1996) found decreased copper content in speciﬁ  c 
areas of the AD brain. The ﬁ  nding of a cerulo-
plasmin proteolysis in the brain supports the oxida-
tive stress hypothesis. This evidence allows to 
suppose that a percentage of ceruloplasmin in the 
brain is not properly formed. Finally, it must be 
remarked that this study had a number of limita-
tions which include: the fact that the AD samples 
used for the serum and brain analyses were from 
different individuals, resulting in a sampling bias; 
the relatively small size and amount of the brain 
samples; the lack of electron paramagnetic reso-
nance (EPR) spectroscopy data to study the ceru-
loplasmin-copper binding afﬁ  nity in AD.
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